Prostate Cancer Vaccines: What’s In The Pipeline?

The sector still attracts the attention of clinical investigators and the pharmaceutical industry, despite disappointing results from another clinical-stage candidate.

Prostate cancer blue ribbon_1200x675

The use of a vaccine-based approach to prostate cancer suffered yet another blow Jan. 11 when Germany’s CureVac AG reported disappointing results for its RNActive prostate cancer vaccine CV9104 in a Phase IIb clinical trial. However, there may be good reasons not to be too downcast; there are more than half-a-dozen other potential therapeutic vaccines in late-stage clinical studies, according to Informa Pharma Intelligence’s database, Biomedtracker.

Not only that, the world’s first therapeutic prostate cancer vaccine, Dendreon Corp.’s Provenge (sipuleucel-T), which was first approved for...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip